The University of Virginia is participating in a clinical trial research study for the adult ages 18 and over, who have an advanced soft tissue sarcoma that is not curable by surgery and for which there is no standard treatment.
The purpose of this study is to compare the combination of ipilimumab and nivolumab with or without cabozantinib to see the effect on tumor progression. The addition of cabozantinib to the nivolumab and ipilimumab combination could stop or slow the growth of your tumor, or it could offer no additional benefit.
This study will help the study doctors find out if adding cabozantinib to the combination of nivolumab and ipilimumab slows or stops growth of your tumors better than nivolumab and ipilimumab.
You will continue receiving study drugs for as long as your cancer does not get worse, the side effects are tolerable, you agree to stay on study, and the study doctor agrees it is still in your best interest to take part in the study
Study-related procedure that are being done beyond your standard of care will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/study/NCT05836571
No Compensation